DE69913548T2 - Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen - Google Patents

Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen Download PDF

Info

Publication number
DE69913548T2
DE69913548T2 DE69913548T DE69913548T DE69913548T2 DE 69913548 T2 DE69913548 T2 DE 69913548T2 DE 69913548 T DE69913548 T DE 69913548T DE 69913548 T DE69913548 T DE 69913548T DE 69913548 T2 DE69913548 T2 DE 69913548T2
Authority
DE
Germany
Prior art keywords
pain
mglur
mglur5
antagonists
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69913548T
Other languages
German (de)
English (en)
Other versions
DE69913548D1 (de
Inventor
Hans Allgeier
David Nicholas COSFORD
Josef Peter FLOR
Fabrizio Gasparini
Conrad Gentsch
D. Stephen HESS
Carl Edwin JOHNSON
Rainer Kuhn
Mark Tricklebank
Laszlo Urban
Andrew Mark VARNEY
Gönül VELI ELEBI
Katharine Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
SIBIA Neurosciences Inc
Original Assignee
Novartis AG
SIBIA Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69913548(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by Novartis AG, SIBIA Neurosciences Inc filed Critical Novartis AG
Application granted granted Critical
Publication of DE69913548D1 publication Critical patent/DE69913548D1/de
Publication of DE69913548T2 publication Critical patent/DE69913548T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
DE69913548T 1998-10-02 1999-09-30 Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen Revoked DE69913548T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9821503 1998-10-02
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
US22081398A 1998-12-23 1998-12-23
US220813 1998-12-23
PCT/EP1999/007239 WO2000020001A1 (en) 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety

Publications (2)

Publication Number Publication Date
DE69913548D1 DE69913548D1 (de) 2004-01-22
DE69913548T2 true DE69913548T2 (de) 2004-09-23

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69913548T Revoked DE69913548T2 (de) 1998-10-02 1999-09-30 Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen

Country Status (21)

Country Link
EP (1) EP1117403B1 (https=)
JP (1) JP2002526408A (https=)
KR (1) KR20010088832A (https=)
CN (1) CN1187048C (https=)
AT (1) ATE255894T1 (https=)
AU (1) AU765644B2 (https=)
BR (1) BR9914215A (https=)
CA (1) CA2345137A1 (https=)
DE (1) DE69913548T2 (https=)
DK (1) DK1117403T3 (https=)
ES (1) ES2213389T3 (https=)
HU (1) HUP0200553A3 (https=)
ID (1) ID29095A (https=)
IL (2) IL142047A0 (https=)
NO (1) NO20011440L (https=)
NZ (1) NZ510743A (https=)
PL (1) PL202906B1 (https=)
PT (1) PT1117403E (https=)
RU (1) RU2232017C2 (https=)
SK (1) SK4382001A3 (https=)
WO (1) WO2000020001A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
KR100545906B1 (ko) * 2000-12-22 2006-01-26 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ 1 길항물질로서의 테트라하이드로-(벤조 또는티에노)-아제핀-피라진 및 트리아진 유도체
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
RS60199B1 (sr) 2015-06-03 2020-06-30 Hoffmann La Roche Derivati etinila
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
EP3459939A1 (en) 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7
KR102027368B1 (ko) * 2018-05-29 2019-10-01 서울대학교산학협력단 통증의 강도를 측정하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68907095T2 (de) * 1988-03-21 1994-01-05 Boehringer Ingelheim Pharma Verbindungen zur Verhinderung der Biosynthese von der Lipoxygenase abgeleiteten Metaboliten der Arachidonsäure.
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
ID29095A (id) 2001-07-26
ES2213389T3 (es) 2004-08-16
AU6198499A (en) 2000-04-26
BR9914215A (pt) 2001-07-03
PT1117403E (pt) 2004-04-30
CN1187048C (zh) 2005-02-02
WO2000020001A1 (en) 2000-04-13
NO20011440D0 (no) 2001-03-21
CA2345137A1 (en) 2000-04-13
RU2232017C2 (ru) 2004-07-10
ATE255894T1 (de) 2003-12-15
EP1117403A1 (en) 2001-07-25
IL142047A0 (en) 2002-03-10
JP2002526408A (ja) 2002-08-20
NO20011440L (no) 2001-05-15
CN1321087A (zh) 2001-11-07
DK1117403T3 (da) 2004-04-13
SK4382001A3 (en) 2001-08-06
PL202906B1 (pl) 2009-08-31
NZ510743A (en) 2003-10-31
IL142047A (en) 2007-09-20
DE69913548D1 (de) 2004-01-22
EP1117403B1 (en) 2003-12-10
KR20010088832A (ko) 2001-09-28
AU765644B2 (en) 2003-09-25
HUP0200553A3 (en) 2002-11-28
HUP0200553A2 (hu) 2002-07-29
PL346876A1 (en) 2002-03-11

Similar Documents

Publication Publication Date Title
DE69913548T2 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
EP2206498B9 (de) Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE69001503T2 (de) D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen.
Carter et al. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties.
DE3876877T2 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE60103384T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit
DE69833451T2 (de) Behandlung der schizophrenie mit ampakinen und neuroleptika
DE69930552T2 (de) Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen
DE68928920T2 (de) Fettsäure-arzneimittel-konjugat zur verabreichung von arzneimitteln durch die blut-gehirn-schranke
DE69936992T2 (de) Bluthochdruckgegenmittelkombination des valsartan und kalziumkanal blocker
EP0861081B1 (de) Verwendung von epinastin für die behandlung von schmerzen
US20040006120A1 (en) Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
DE69626610T2 (de) Produkt enthaltend Rapamycin oder ausgewählte Derivate und einen NMDA- oder AMPA-Antagonisten zur Verwendung für die Behandlung von Epilepsie oder Morbus Huntington, und die Verwendung von Rapamycin oder von ausgewählten Derivaten für die Herstellung eines Medikaments für die Behandlung von Epilepsie oder Morbus Huntington.
DE69933874T2 (de) Topische zusammensetzung enthaltend ein opioid-analgetika und einen nmda-antagonist
DE69327328T2 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
DE69837387T2 (de) (d)-METHADON, EIN NICHT-OPIOIDES SCHMERZMITTEL
EP0193056A1 (de) Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
Keegan Muscle relaxants and neuromuscular blockade
Kuhn et al. Stimulus properties of the narcotic antagonist pentazocine: similarity to morphine and antagonism by naloxone.
US20010056084A1 (en) MGluR5 antagonists for the treatment of pain and anxiety
DE69933450T2 (de) Imidazolin-rezeptor-bindende verbindungen
Lorrai et al. Reducing effect of the novel positive allosteric modulator of the GABAB receptor, COR659, on binge-like alcohol drinking in male mice and rats
EP0516795B1 (de) Arzneimittel enthaltend einen quisqualat-rezeptor-antagonisten und einen dopamin-agonisten zur behandlung des morbus parkinson
DE60213365T2 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
CA2044854A1 (en) Method for preventing or treating urinary incontinence

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8331 Complete revocation